1 Market Overview
1.1 Product Overview and Scope of Anti-nuclear Antibody (ANA) Testing
1.2 Classification of Anti-nuclear Antibody (ANA) Testing by Type
1.2.1 Overview: Global Anti-nuclear Antibody (ANA) Testing Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Anti-nuclear Antibody (ANA) Testing Revenue Market Share by Type in 2020
1.2.3 Indirect Immunofluorescence
1.2.4 Enzyme-linked Immunosorbent Assay (ELISA)
1.2.5 Other
1.3 Global Anti-nuclear Antibody (ANA) Testing Market by Application
1.3.1 Overview: Global Anti-nuclear Antibody (ANA) Testing Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Global Anti-nuclear Antibody (ANA) Testing Market Size & Forecast
1.5 Global Anti-nuclear Antibody (ANA) Testing Market Size and Forecast by Region
1.5.1 Global Anti-nuclear Antibody (ANA) Testing Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Anti-nuclear Antibody (ANA) Testing Market Size by Region, (2016-2021)
1.5.3 North America Anti-nuclear Antibody (ANA) Testing Market Size and Prospect (2016-2026)
1.5.4 Europe Anti-nuclear Antibody (ANA) Testing Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Anti-nuclear Antibody (ANA) Testing Market Size and Prospect (2016-2026)
1.5.6 South America Anti-nuclear Antibody (ANA) Testing Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Anti-nuclear Antibody (ANA) Testing Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Anti-nuclear Antibody (ANA) Testing Market Drivers
1.6.2 Anti-nuclear Antibody (ANA) Testing Market Restraints
1.6.3 Anti-nuclear Antibody (ANA) Testing Trends Analysis
2 Company Profiles
2.1 Abcam
2.1.1 Abcam Details
2.1.2 Abcam Major Business
2.1.3 Abcam Anti-nuclear Antibody (ANA) Testing Product and Solutions
2.1.4 Abcam Anti-nuclear Antibody (ANA) Testing Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Abcam Recent Developments and Future Plans
2.2 Antibodies
2.2.1 Antibodies Details
2.2.2 Antibodies Major Business
2.2.3 Antibodies Anti-nuclear Antibody (ANA) Testing Product and Solutions
2.2.4 Antibodies Anti-nuclear Antibody (ANA) Testing Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Antibodies Recent Developments and Future Plans
2.3 Bio-Rad Laboratories
2.3.1 Bio-Rad Laboratories Details
2.3.2 Bio-Rad Laboratories Major Business
2.3.3 Bio-Rad Laboratories Anti-nuclear Antibody (ANA) Testing Product and Solutions
2.3.4 Bio-Rad Laboratories Anti-nuclear Antibody (ANA) Testing Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Bio-Rad Laboratories Recent Developments and Future Plans
2.4 Alere
2.4.1 Alere Details
2.4.2 Alere Major Business
2.4.3 Alere Anti-nuclear Antibody (ANA) Testing Product and Solutions
2.4.4 Alere Anti-nuclear Antibody (ANA) Testing Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Alere Recent Developments and Future Plans
2.5 Erba Diagnostics
2.5.1 Erba Diagnostics Details
2.5.2 Erba Diagnostics Major Business
2.5.3 Erba Diagnostics Anti-nuclear Antibody (ANA) Testing Product and Solutions
2.5.4 Erba Diagnostics Anti-nuclear Antibody (ANA) Testing Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Erba Diagnostics Recent Developments and Future Plans
2.6 MBL International
2.6.1 MBL International Details
2.6.2 MBL International Major Business
2.6.3 MBL International Anti-nuclear Antibody (ANA) Testing Product and Solutions
2.6.4 MBL International Anti-nuclear Antibody (ANA) Testing Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 MBL International Recent Developments and Future Plans
2.7 Merck
2.7.1 Merck Details
2.7.2 Merck Major Business
2.7.3 Merck Anti-nuclear Antibody (ANA) Testing Product and Solutions
2.7.4 Merck Anti-nuclear Antibody (ANA) Testing Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Merck Recent Developments and Future Plans
2.8 Indur Services
2.8.1 Indur Services Details
2.8.2 Indur Services Major Business
2.8.3 Indur Services Anti-nuclear Antibody (ANA) Testing Product and Solutions
2.8.4 Indur Services Anti-nuclear Antibody (ANA) Testing Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Indur Services Recent Developments and Future Plans
2.9 Trinity Biotech
2.9.1 Trinity Biotech Details
2.9.2 Trinity Biotech Major Business
2.9.3 Trinity Biotech Anti-nuclear Antibody (ANA) Testing Product and Solutions
2.9.4 Trinity Biotech Anti-nuclear Antibody (ANA) Testing Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Trinity Biotech Recent Developments and Future Plans
2.10 Thermo Fisher Scientific
2.10.1 Thermo Fisher Scientific Details
2.10.2 Thermo Fisher Scientific Major Business
2.10.3 Thermo Fisher Scientific Anti-nuclear Antibody (ANA) Testing Product and Solutions
2.10.4 Thermo Fisher Scientific Anti-nuclear Antibody (ANA) Testing Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Thermo Fisher Scientific Recent Developments and Future Plans
2.11 Zeus Scientific
2.11.1 Zeus Scientific Details
2.11.2 Zeus Scientific Major Business
2.11.3 Zeus Scientific Anti-nuclear Antibody (ANA) Testing Product and Solutions
2.11.4 Zeus Scientific Anti-nuclear Antibody (ANA) Testing Revenue, Gross Margin and Market Share (2019-2021)
2.11.5 Zeus Scientific Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Anti-nuclear Antibody (ANA) Testing Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Anti-nuclear Antibody (ANA) Testing Players Market Share
3.2.2 Top 10 Anti-nuclear Antibody (ANA) Testing Players Market Share
3.2.3 Market Competition Trend
3.3 Anti-nuclear Antibody (ANA) Testing Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Anti-nuclear Antibody (ANA) Testing Revenue and Market Share by Type (2016-2021)
4.2 Global Anti-nuclear Antibody (ANA) Testing Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Anti-nuclear Antibody (ANA) Testing Revenue Market Share by Application (2016-2021)
5.2 Anti-nuclear Antibody (ANA) Testing Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Anti-nuclear Antibody (ANA) Testing Revenue by Type (2016-2026)
6.2 North America Anti-nuclear Antibody (ANA) Testing Revenue by Application (2016-2026)
6.3 North America Anti-nuclear Antibody (ANA) Testing Market Size by Country
6.3.1 North America Anti-nuclear Antibody (ANA) Testing Revenue by Country (2016-2026)
6.3.2 United States Anti-nuclear Antibody (ANA) Testing Market Size and Forecast (2016-2026)
6.3.3 Canada Anti-nuclear Antibody (ANA) Testing Market Size and Forecast (2016-2026)
6.3.4 Mexico Anti-nuclear Antibody (ANA) Testing Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Anti-nuclear Antibody (ANA) Testing Revenue by Type (2016-2026)
7.2 Europe Anti-nuclear Antibody (ANA) Testing Revenue by Application (2016-2026)
7.3 Europe Anti-nuclear Antibody (ANA) Testing Market Size by Country
7.3.1 Europe Anti-nuclear Antibody (ANA) Testing Revenue by Country (2016-2026)
7.3.2 Germany Anti-nuclear Antibody (ANA) Testing Market Size and Forecast (2016-2026)
7.3.3 France Anti-nuclear Antibody (ANA) Testing Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Anti-nuclear Antibody (ANA) Testing Market Size and Forecast (2016-2026)
7.3.5 Russia Anti-nuclear Antibody (ANA) Testing Market Size and Forecast (2016-2026)
7.3.6 Italy Anti-nuclear Antibody (ANA) Testing Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Anti-nuclear Antibody (ANA) Testing Revenue by Type (2016-2026)
8.2 Asia-Pacific Anti-nuclear Antibody (ANA) Testing Revenue by Application (2016-2026)
8.3 Asia-Pacific Anti-nuclear Antibody (ANA) Testing Market Size by Region
8.3.1 Asia-Pacific Anti-nuclear Antibody (ANA) Testing Revenue by Region (2016-2026)
8.3.2 China Anti-nuclear Antibody (ANA) Testing Market Size and Forecast (2016-2026)
8.3.3 Japan Anti-nuclear Antibody (ANA) Testing Market Size and Forecast (2016-2026)
8.3.4 South Korea Anti-nuclear Antibody (ANA) Testing Market Size and Forecast (2016-2026)
8.3.5 India Anti-nuclear Antibody (ANA) Testing Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Anti-nuclear Antibody (ANA) Testing Market Size and Forecast (2016-2026)
8.3.7 Australia Anti-nuclear Antibody (ANA) Testing Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Anti-nuclear Antibody (ANA) Testing Revenue by Type (2016-2026)
9.2 South America Anti-nuclear Antibody (ANA) Testing Revenue by Application (2016-2026)
9.3 South America Anti-nuclear Antibody (ANA) Testing Market Size by Country
9.3.1 South America Anti-nuclear Antibody (ANA) Testing Revenue by Country (2016-2026)
9.3.2 Brazil Anti-nuclear Antibody (ANA) Testing Market Size and Forecast (2016-2026)
9.3.3 Argentina Anti-nuclear Antibody (ANA) Testing Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Anti-nuclear Antibody (ANA) Testing Revenue by Type (2016-2026)
10.2 Middle East & Africa Anti-nuclear Antibody (ANA) Testing Revenue by Application (2016-2026)
10.3 Middle East & Africa Anti-nuclear Antibody (ANA) Testing Market Size by Country
10.3.1 Middle East & Africa Anti-nuclear Antibody (ANA) Testing Revenue by Country (2016-2026)
10.3.2 Turkey Anti-nuclear Antibody (ANA) Testing Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Anti-nuclear Antibody (ANA) Testing Market Size and Forecast (2016-2026)
10.3.4 UAE Anti-nuclear Antibody (ANA) Testing Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
【掲載企業】
Abcam、Antibodies、Bio-Rad Laboratories、Alere、Erba Diagnostics、MBL International、Merck、Indur Services、Trinity Biotech、Thermo Fisher Scientific、Zeus Scientific
【免責事項】
https://www.globalresearch.jp/disclaimer